The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents

被引：53

作者：

Lloyd, GK ^{[1
]}

Menzaghi, F ^{[1
]}

Bontempi, B ^{[1
]}

Suto, C ^{[1
]}

Siegel, R ^{[1
]}

Akong, M ^{[1
]}

Stauderman, K ^{[1
]}

Velicelebi, G ^{[1
]}

Johnson, E ^{[1
]}

Harpold, MM ^{[1
]}

Rao, TS ^{[1
]}

Sacaan, AI ^{[1
]}

Chavez-Noriega, LE ^{[1
]}

Washburn, MS ^{[1
]}

Vernier, JM ^{[1
]}

Cosford, NDP ^{[1
]}

McDonald, LA ^{[1
]}

机构：

[1] SIBIA Neurosci Inc, La Jolla, CA 92037 USA

来源：

LIFE SCIENCES | 1998年 / 62卷 / 17-18期

关键词：

SIB-1508Y; SIB-1553A; nicotinic acetylcholine receptors; cognition; locomotion;

D O I：

10.1016/S0024-3205(98)00114-3

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Neuronal nicotinic acetylcholine receptors (NAChRs) are pentameric ligand-gated ion channel receptors which exist as different functional subunit combinations which apparently subserve different physiological functions as indicated by molecular biological and pharmacological techniques. It is possible to design and synthesize novel compounds that have greater selective affinities and efficacies than nicotine for different NAChRs, which should translate into different behavioral pro files and therapeutic potentials. Examples of NAChR agonists studied are nicotine, SIB-1508Y, SIB-1553A and epibatidine. These compounds have different degrees of selectivity for human recombinant NAChRs, different neurotransmitter release profiles in vitro and in vivo and differential behavioral profiles. Preclinical studies suggest that SIB-1508Y is a candidate for the treatment of the motor and cognitive deficits of Parkinson's disease, whereas SIB-1553A appears to have potential as a candidate for the treatment of Alzheimer's disease. Epibatidine has a strong analgesic profile, however the ratio between pharmacological activity and undesirable effects is so low that it is difficult to envisage the use of this compound therapeutically. Nicotine has a broad profile of pharmacological activity, for instance demonstrating activity in models for cognition and analgesia. As for epibatidine, the adverse effects of nicotine severely limits its therapeutic use in humans. The discovery of subtype-selective NAChR agonists such as SIB-1508Y and SIB-1553A provides a new class of neuropsychopharmacological agents with better therapeutic ratios than nonspecific agents such as nicotine.

引用

页码：1601 / 1606

页数：6

共 22 条

[1]

BONTEMPI B, 1997, SOC NEUR ABS, V23

[2]

CamposCaro A, 1997, J NEUROCHEM, V68, P488

[3]

CHAVEZNORIEGA LE, 1997, IBC C NACHR PHARM TA

[4] Comparative structure of human neuronal alpha 2-alpha 7 and beta 2-beta 4 nicotinic acetylcholine receptor subunits and functional expression of the alpha 2, alpha 3, alpha 4, alpha 7, beta 2, and beta 4 subunits [J].

Elliott, KJ ;

Ellis, SB ;

Berckhan, KJ ;

Urrutia, A ;

ChavezNoriega, LE ;

Johnson, EC ;

Velicelebi, G ;

Harpold, MM .

JOURNAL OF MOLECULAR NEUROSCIENCE, 1996, 7 (03) :217-228

[5]

ELLIOTT KJ, 1996, SOC NEUR ABS, V2

[6] Nicotinic receptor function in schizophrenia [J].

Leonard, S ;

Adams, C ;

Breese, CR ;

Adler, LE ;

Bickford, P ;

Byerley, W ;

Coon, H ;

Griffith, JM ;

Miller, C ;

MylesWorsley, M ;

Nagamoto, HT ;

Rollins, Y ;

Stevens, KE ;

Waldo, M ;

Freedman, R .

SCHIZOPHRENIA BULLETIN, 1996, 22 (03) :431-445

[7]

LLOYD GK, 1997, PHARMACOLOGIST, V39, P103

[8]

LLOYD GK, 1995, SOC NEUR ABS, V21

[9]

Menzaghi F, 1997, J PHARMACOL EXP THER, V280, P384

[10]

Menzaghi F, 1997, J PHARMACOL EXP THER, V280, P393

← 1 2 3 →